Vestal Point Buys $181.8M Stake Despite 1,300% Rally
Vestal Point Capital established a new $181.80 million position in Terns Pharmaceuticals during the fourth quarter, signaling strong institutional conviction despite the stock's explosive performance. According to a February 17, 2026 regulatory filing, the fund acquired 4,500,000 shares, making Terns its third-largest holding at 6.7% of its managed assets. The purchase occurred as Terns' stock price concluded a staggering 1,300% climb over the past year, closing at $46.07 per share as of Monday. This performance dramatically outpaced the S&P 500's approximate 19% gain during the same period, demonstrating that the massive run-up did not deter the institutional investor.
Pipeline and $1B Cash Hoard Drive Bullish Bet
Vestal Point's investment appears to be a calculated bet on Terns' development pipeline and its exceptionally strong financial position. The clinical-stage biotech focuses on small-molecule therapies for high-demand markets like non-alcoholic steatohepatitis (NASH), obesity, and certain cancers. Its pipeline includes promising candidates such as TERN-501 for metabolic liver disease and TERN-701 for chronic myeloid leukemia. A key factor de-risking this investment is Terns' balance sheet, which holds approximately $1 billion in cash and marketable securities. This substantial reserve is sufficient to fund operations and clinical milestones well into the next decade, providing a long runway to bring its drug candidates to market.
